Open AccessCURRENT POINT OF VIEW ON PROGNOSTIC AND PREDICTIVE ROLES AND PRACTICAL APPLICATION OF HER2 RECEPTOR’S DETECTION. LITERATURE REVIEW
Author(s) -
Д. Л. Ротин,
Oxana Paklina,
И. О. Тинькова,
Д. Н. Греков,
Г. Р. Сетдикова
Publication year - 2020
Publication title -
rossijskij bioterapevtičeskij žurnal
Language(s) - English
Resource type - Journals
eISSN - 1726-9792
pISSN - 1726-9784
DOI - 10.17650/1726-9784-2019-19-2-6-12
Subject(s) - cancer , breast cancer , trastuzumab , oncogene , medicine , stomach cancer , oncology , immunohistochemistry , biopsy , cell cycle
Human epidermal growth factor receptor HER2, a proto-oncogene involved in the proliferation and differentiation signaling pathway. The overexpression and amplification of the HER2 gene and their significance have been studied in breast cancer. Data on HER2 overexpression in gastric cancer vary widely, and the value is presented by inconsistent disparate data. The interpretation of HER2 in gastriccancer differs from the evaluation in breast cancer. The purpose of this review is to summarize current data on the evaluation of HER2in gastric cancer for the selection of targeted therapy. The search in modern databases of medical literature was carried out, more than100 modern literary sources on the above-mentioned topic were studied and analyzed in detail and carefully. The most significant dataon the evaluation of HER2 expression in gastric cancer and its prognostic and predictive value were selected and presented. Selectedoptions evaluate the expression of HER2 receptor in operating and biopsy material of stomach cancer. Comparative data on the use of different antibody clones to solve the above problem are presented. The most frequent and important errors and possible interpretationdisorders in the expression of HER2 in gastric cancer are analyzed. The use of transtuzumab for targeted therapy in gastric cancer makesit mandatory to test surgical and biopsy samples of gastric cancer to assess their expression of HER2. The development of various methodsand the progress of molecular biology, however, the main role of the immunohistochemical method in solving this problem still left. Gastriccancer needs a single accessible standardized system for evaluating HER2 expression, and, most importantly, expert level interpretationof these results.